Abrysvo® (respiratory syncytial virus vaccine) – New indication
October 22, 2024 - Pfizer announced the FDA approval of Abrysvo (respiratory syncytial virus [RSV] vaccine), for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.